Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Shun Lu, MD"'
Autor:
Jie Wang, MD, PhD, Yi-Long Wu, MD, Shun Lu, MD, PhD, Qun Wang, MD, Shanqing Li, MD, Wen-Zhao Zhong, MD, PhD, Qiming Wang, MD, Wei Li, MD, PhD, Buhai Wang, MD, Jun Chen, MD, Ying Cheng, MD, Hongbing Duan, MD, Gaofeng Li, MD, Li Shan, MD, Yangbo Liu, MS, Jing Liu, MD, Xiangning Huang, PhD, Ana Bolanos, MD, Jie He, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100621- (2024)
Introduction: In Chinese patients with NSCLC, prevalence of EGFR-mutated (EGFRm) disease is high. In the global phase 3 ADAURA study (NCT02511106), adjuvant osimertinib was found to have a statistically significant and clinically meaningful improveme
Externí odkaz:
https://doaj.org/article/a94bd03454c54595bceebab2019eeee9
Autor:
Qing Zhou, MD, PhD, Ross A. Soo, MBBS, PhD, Gee-Chen Chang, MD, PhD, Chao-Hua Chiu, MD, Hidetoshi Hayashi, MD, PhD, Sang-We Kim, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Jianying Zhou, MD, Victor Ho-Fun Lee, MD, Dong-Wan Kim, MD, PhD, Baohui Han, MD, PhD, James Chung Man Ho, MD, FRCP, Chia-Chi Lin, MD, PhD, Shun Lu, MD, Anna Polli, BS, Anna Maria Calella, PhD, Jean-François Martini, PhD, Chew Hooi Wong, PhD, Tony Mok, MD, Hye Ryun Kim, MD, PhD, Yi-Long Wu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 5, Pp 100499- (2023)
Introduction: Lorlatinib is a potent, third-generation inhibitor of ALK. In the planned interim analysis of the ongoing, phase 3, randomized, global CROWN trial (NCT03052608), lorlatinib resulted in significantly longer progression-free survival than
Externí odkaz:
https://doaj.org/article/c09913d79c7448e094d8c942679bfbff
Autor:
Xiaorong Dong, MD, PhD, Xingya Li, MD, Jianhua Chen, MD, Shenglin Ma, MD, Deguang Mu, MD, Jie Hu, MD, PhD, Shun Lu, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 2, Pp 100449- (2023)
Introduction: c-MET is an important therapeutic target for various cancers; however, the People’s Republic of China currently retails only one specific c-MET inhibitor. Our preclinical study has revealed the high selectivity of HS-10241 to suppress
Externí odkaz:
https://doaj.org/article/7a976e919ca64687a5bc34303f3eb7b5
Autor:
Yi-Long Wu, MD, Shun Lu, MD, PhD, James Chih-Hsin Yang, MD, PhD, Jianying Zhou, MD, Takashi Seto, MD, Myung-Ju Ahn, MD, PhD, Wu-Chou Su, MD, Noboru Yamamoto, MD, PhD, Dong-Wan Kim, MD, PhD, Jolanda Paolini, MSc, Tiziana Usari, BSc, Laura Iadeluca, PhD, Keith D. Wilner, PhD, Koichi Goto, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 10, Pp 100406- (2022)
Introduction: Crizotinib provided meaningful clinical benefit in the initial analysis of a phase 2 study in East Asian patients with advanced ROS1-positive NSCLC (NCT01945021). Nevertheless, overall survival (OS) data were immature. Here, we present
Externí odkaz:
https://doaj.org/article/7369e36175e44454b80a3ac673b3634f
Autor:
Shun Lu, MD, Jian Fang, MD, Xingya Li, MD, Lejie Cao, MD, Jianying Zhou, MD, Qisen Guo, MD, Zongan Liang, MD, Ying Cheng, MD, Liyan Jiang, MD, Nong Yang, MD, Zhigang Han, MD, Jianhua Shi, MD, Yuan Chen, MD, Hua Xu, MD, Helong Zhang, MD, Gongyan Chen, MD, Rui Ma, MD, Sanyuan Sun, MD, Yun Fan, MD, Songhua Fan, MD, Jie Yu, MD, Puhan Lu, PhD, Xian Luo, MS, Weiguo Su, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 10, Pp 100407- (2022)
Introduction: Savolitinib has been found to have encouraging antitumor activity and a favorable safety profile in Chinese patients with pulmonary sarcomatoid carcinoma and other NSCLCs with MET exon 14 skipping alterations (MET ex14 positive) at the
Externí odkaz:
https://doaj.org/article/a7ca95375de14255b657fbafab37ec69
Autor:
Alexander Drilon, MD, Chao-Hua Chiu, MD, Yun Fan, MD, Byoung Chul Cho, MD, PhD, Shun Lu, MD, PhD, Myung-Ju Ahn, MD, PhD, Matthew G. Krebs, MD, PhD, Stephen V. Liu, MD, Thomas John, MD, Gregory A. Otterson, MD, Daniel S.W. Tan, MD, Tejas Patil, MD, Rafal Dziadziuszko, MD, PhD, Erminia Massarelli, MD, PhD, Takashi Seto, MD, Robert C. Doebele, MD, PhD, Bethany Pitcher, MSc, Nino Kurtsikidze, MD, Sebastian Heinzmann, PhD, Salvatore Siena, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100332- (2022)
Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer fo
Externí odkaz:
https://doaj.org/article/46b674c9f39d4db4b8d61e682c4faee9
Autor:
James Chih-Hsin Yang, MD, PhD, Tony S.K. Mok, MD, Shun Lu, MD, Kazuhiko Nakagawa, MD, PhD, Nobuyuki Yamamoto, MD, Yuan-Kai Shi, MD, Li Zhang, MD, Ross A. Soo, M.B.B.S., PhD, Satoshi Morita, PhD, Tomohide Tamura, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 3, Pp 100142- (2021)
Introduction: Despite recent advances in NSCLC treatment, specific data on the elderly population remain limited. In this post hoc subgroup analysis of the East Asia S-1 Trial in Lung Cancer (EAST-LC) trial, we compared S-1 and docetaxel (DTX) in pat
Externí odkaz:
https://doaj.org/article/789f40ff2e624800b8f722aef5b2ae98